Ensign Peak Advisors
PHAT icon

Ensign Peak Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Ensign Peak Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1M Sell
1,627,806
-724,214
-31% -$9.15M 0.03% 318
2025
Q4 		$39M Sell
2,352,020
-151,324
-6% -$2.16M 0.07% 209
2025
Q3 		$29.5M Sell
2,503,344
-16,628
-0.7% -$172K 0.05% 257
2025
Q2 		$24.2M Buy
2,519,972
+5,688
+0.2% +$31.5K 0.04% 284
2025
Q1 		$15.8M Sell
2,514,284
-12,770
-0.5% -$77.5K 0.03% 350
2024
Q4 		$20.5M Sell
2,527,054
-54,334
-2% -$673K 0.04% 317
2024
Q3 		$46.7M Buy
2,581,388
+336,560
+15% +$4.7M 0.08% 194
2024
Q2 		$23.1M Sell
2,244,828
-35,172
-2% -$362K 0.04% 293
2024
Q1 		$24.2M Hold
2,280,000
– – 0.04% 290
2023
Q4 		$20.8M Buy
2,280,000
+547,828
+32% +$4.72M 0.04% 292
2023
Q3 		$18M Sell
1,732,172
-24,955
-1% -$342K 0.04% 284
2023
Q2 		$25.2M Sell
1,757,127
-4,064
-0.2% -$46.9K 0.05% 259
2023
Q1 		$12.6M Hold
1,761,191
– – 0.03% 363
2022
Q4 		$19.8M Hold
1,761,191
– – 0.04% 294
2022
Q3 		$19.5M Buy
1,761,191
+85,703
+5% +$817K 0.05% 276
2022
Q2 		$14.1M Buy
1,675,488
+570,729
+52% +$5.87M 0.03% 321
2022
Q1 		$15M Sell
1,104,759
-210,958
-16% -$3.41M 0.03% 341
2021
Q4 		$25.9M Buy
1,315,717
+145,493
+12% +$3.42M 0.05% 274
2021
Q3 		$37.6M Sell
1,170,224
-49,786
-4% -$1.65M 0.08% 209
2021
Q2 		$41.3M Sell
1,220,010
-19,452
-2% -$697K 0.08% 203
2021
Q1 		$46.6M Buy
1,239,462
+14,910
+1% +$624K 0.1% 178
2020
Q4 		$40.7M Buy
1,224,552
+331,760
+37% +$13.4M 0.09% 189
2020
Q3 		$32.7M Buy
892,792
+42,789
+5% +$1.48M 0.08% 205
2020
Q2 		$28M Buy
850,003
+252,511
+42% +$9.7M 0.08% 224
2020
Q1 		$15.4M Sell
597,492
-19,365
-3% -$647K 0.05% 275
2019
Q4 		$19.2M Buy
+616,857
New +$15.5M 0.05% 298

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

Ensign Peak Advisors's PHAT Position: Q1 2026 in Review

Ensign Peak Advisors reduced its Phathom Pharmaceuticals (PHAT) stake by 31% in Q1 2026, selling an estimated $9.15M and leaving 1,627,806 shares worth $18.1M. The position accounts for 0.03% of the portfolio, ranked #318.

Ensign Peak Advisors first reported a position in PHAT in Q4 2019 and has held it in 26 quarters since. The position peaked at $46.7M in Q3 2024. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Ensign Peak Advisors held 1,627,806 shares of Phathom Pharmaceuticals worth $18.1M as of Q1 2026.
  • Ensign Peak Advisors sold 724,214 Phathom Pharmaceuticals shares in Q1 2026, an estimated $9.15M.
  • Phathom Pharmaceuticals made up 0.03% of Ensign Peak Advisors's portfolio in Q1 2026, its #318 holding.
  • Ensign Peak Advisors first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Phathom Pharmaceuticals position peaked at $46.7M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.